Macroplastique showed no clear difference in number of children with afebrile UTI compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (low certainty).
Macroplastique probably leads to lower number of ureters with persistent VUR > grade 1 at 1 year compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (moderate certainty).
Macroplastique may leads to higher number of kidneys with temporary renal dilatation after injection compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (low certainty).
Macroplastique showed no clear difference in ureteral obstruction compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (low certainty).
Macroplastique showed no clear difference in post operative flank pain compared with dextranomer/hyaluronic acid polymer (Deflux) to correct… (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
It is very uncertain whether tonsillectomy plus standard care changes relapse of haematuria (macroscopic) compared with standard care (very low certainty).
Angiotensin receptor blockers may leads to lower micro‐ to macroalbuminuria Median compared with placebo or no treatment (low certainty).
Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).
Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
The review found no eligible studies for this question.
Angiotensin receptor blocker (ARB) showed no clear difference in micro‐ to macroalbuminuria 8 compared with another ARB (low certainty).
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to macroalbuminuria Median compared with placebo or no treatment (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.